Ralph V. Boccia, MD, FACP, discusses step-up dosing workflows, REMS, staff training, caregivers, and hospital partnerships for bispecifics.
Poll|Poll|May 11, 2012
A 54-Year-Old Woman Notes the Abundant Development of Nonpigmented Hair on Her Ears and Nose
Author(s)Ted Rosen, MD
Advertisement
A 54-year-old woman, previously in excellent health, noted the insidious development of abundant, thin, and softly textured, nonpigmented hair on her ears and nose. A detailed review of systems was entirely negative, and both a complete blood count and automated routine biochemistry panel were normal. Gynecologic examination, including a pap smear, was normal one year prior to presentation. The patient was a lifelong nonsmoker and nondrinker. Family history was negative for cancer.
From what specific disorder does she suffer?
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
4
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
5